Health Care & Life Sciences » Pharmaceuticals | Schnell Biopharmaceuticals Inc.

Schnell Biopharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
20,852
4,396
1,553
4,767
16,891
1,215
Depreciation, Depletion & Amortization
790
1,387
1,599
1,340
1,653
1,462
Other Funds
-
57
10
-
-
476
Funds from Operations
4,911
2,725
1,812
1,603
125
723
Changes in Working Capital
3,210
4,192
35
3,664
9,011
609
Net Operating Cash Flow
1,702
6,917
1,847
2,061
8,886
1,331
Capital Expenditures
9,701
2,195
7,535
2,820
2,649
Sale of Fixed Assets & Businesses
130
-
401
155
1,779
Purchase/Sale of Investments
5,383
6,468
13,512
32,904
30,225
Net Investing Cash Flow
1,724
15,015
10,051
35,526
33,941
Issuance/Reduction of Debt, Net
4,378
13,343
3,738
42,555
9,618
Net Financing Cash Flow
3,765
13,287
3,305
43,366
40,455
Net Change in Cash
3,769
8,641
8,596
5,777
2,390
Free Cash Flow
11,149
8,911
3,522
3,759
10,990
Net Assets from Acquisitions
-
-
-
-
879
Other Sources
30,099
12,151
8,365
815
4,568
Change in Capital Stock
8,143
-
443
851
50,073
Exchange Rate Effect
18
5
3
2
18
Other Uses
13,422
18,503
4,692
771
6,535

About Schnell Biopharmaceuticals

View Profile
Address
Room 301 Gangho Building
Seoul SL 06735
Korea, Republic Of
Employees -
Website http://www.aprogen-pharm.com
Updated 07/08/2019
Aprogen Pharmaceuticals, Inc. engages in the manufacture and sale of pharmaceutical products. It operates throught the Pharmaceutical Manufacturing and Wholesale business divisions. The Pharmaceutical Manufacturing division provides antibiotics, antirhematics, and medicines for dermatopathy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.